Bank of America Securities Maintains a Buy Rating on Incyte Corporation (INCY), Sets a $104 PT

Incyte Corporation (NASDAQ:INCY) is one of the best affordable biotech stocks to invest in now. In a report released on September 15, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Incyte Corporation (NASDAQ:INCY) and set a price target of $104.00.

Incyte Corporation (NASDAQ:INCY) reported total revenues of $1.216 billion in its fiscal Q2 2025 results, up 16% year-over-year. Total product revenues for the quarter reached $1.059 billion, up 17% year-over-year.

Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics, focusing on oncology, hematology, inflammation, and autoimmunity therapeutic areas.

While we acknowledge the potential of INCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.